Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Hallelujah

<< Previous

Bullboard Posts

Next >>

Comment by Lee430on Apr 09, 2021 10:36am

118 Views

Post# 32966211

RE:RE:RE:Hallelujah

Guess I am not the only one that is frustrated with the IR efforts so far, possibly they have a big push planned for after AACR.... At what point does the board say this is not working as we expected and step in to make changes?

scarlet1967 wrote: Hi Leo,
It is posted on Stocktwits not by IR but it is there. The IR lady my guess must be working hard on other much more important things than IR , pedicure, manicure...

Lee430 wrote: Scarlet1967, Has the first TH1902 dosage article and Newscast been shared on retail investor sites like Stocktwits? is our IR director promoting these pieces?

scarlet1967 wrote: Officially the company is in phase 1 oncology program.
https://www.theratech.com/products/th-1902/